Nebula Genomics Drug Response: What You'll Actually See in a Report From Your WGS Data

This is the practical walkthrough: here is what your Gene2Rx report actually shows, drug by drug. To be clear about who does what: Nebula Genomics gives you the VCF file from your whole genome sequencing, and Gene2Rx turns that file into the report. So when you upload your Nebula VCF to Gene2Rx, here is what actually shows up, which medications get flagged, what the recommendations say, and how to use them with your doctor. The full report covers 110 medications on the same CPIC and FDA guidelines clinicians use, runs in minutes, and costs $5 for a starter report or $49 for the full version, plus a $15 surcharge for WGS and VCF uploads because they take more processing (so a full report is $64). (If you are new to pharmacogenetics, read the overview guide first.)

When your doctor writes a prescription, they are making an educated guess that the standard dose will work for you. For most patients it does. For a meaningful minority it does not. A drug response report tells you in advance which medications are worth closer attention, based on your genotype. You do not need a new test for this if you have Nebula WGS data; the relevant genetic markers are already in the VCF you can download and hand to Gene2Rx.

Gene2Rx groups medications by your metabolizer phenotype for each relevant gene. A typical output for someone who turns out to be a CYP2D6 ultrarapid metabolizer with a DPYD intermediate finding: tramadol flagged with a do-not-use warning (risk of severe toxicity from over-activation), codeine flagged similarly, and capecitabine flagged with a 25 to 50 percent dose-reduction note if chemotherapy ever comes up. Each flag links to the underlying CPIC or FDA guideline so you can see exactly what the clinical basis is. This is the Gene2Rx report, not anything Nebula produces; Nebula only supplies the VCF underneath it.

The concrete place WGS data helps your drug response report is rare-variant coverage. A genotyping chip only reads pre-selected positions, so rare loss-of-function variants in genes like DPYD, TPMT, and CYP2C19 can be missed entirely, while a Nebula VCF includes them. That especially helps patients whose ancestry is under-represented in consumer-array design. One important limit: CYP2D6 ultrarapid status is usually caused by gene duplication, and copy-number changes like that require raw alignment data Gene2Rx does not process. Gene2Rx works from the variant calls in your VCF, so it does not detect CYP2D6 duplications or deletions, and the report does not flag duplication-based ultrarapid status.

Most prescribing clinicians will accept a pharmacogenetic report as useful information, especially for medications where CPIC has published dosing guidelines. Practical approach: share the report before your next prescription decision (not after a medication has already failed you), highlight the recommendations relevant to what you are discussing, and let your clinician decide how to weigh them. Because your phenotype is a lifelong fact, much of the report is about drugs you are not taking yet: someone who learns at 40 they are DPYD intermediate is storing information that matters enormously if an oncologist ever reaches for capecitabine. The report never expires because your DNA does not change.

Here are specific phenotype outputs you will see in your Gene2Rx report, and what each means for drug response in practice. The phenotype is read from your Nebula VCF; the interpretation is Gene2Rx's.

Your Nebula VCF contains the genotype calls for all of these. Gene2Rx extracts them, maps them to CPIC^[8] and FDA^[9] phenotype categories, and produces the report. The WGS data advantage is most meaningful for rare-variant carriers, whose variants a genotyping chip may never probe. For patients who are normal metabolizers for everything, WGS and consumer-array data give the same answer. Note that Gene2Rx does not call CYP2D6 copy-number changes (gene duplications or deletions) from a VCF, because that requires raw alignment data we do not process.

The highest-value moments to pull up your drug response report: before starting any new antidepressant, before a procedure where an opioid might be prescribed (codeine and tramadol are the main pharmacogenetically sensitive ones), before starting a statin (SLCO1B1 muscle-pain risk)^[5] or clopidogrel after a cardiac event, before starting warfarin (both CYP2C9 and VKORC1 matter),^[4] and before any chemotherapy involving fluoropyrimidines (capecitabine, fluorouracil) or thiopurines (azathioprine, mercaptopurine).

• Dante Labs Pharmacogenetics: Turn Your Dante WGS Data Into a PGx Report
• Sequencing.com Pharmacogenetics: Turn Your WGS Data Into a PGx Report
• VCF Pharmacogenetics: Turn Any VCF File Into a Pharmacogenetic Report
• Whole Genome Sequencing for Pharmacogenetics: A Complete Guide
• Nucleus Genomics Pharmacogenetics: Use Your Nucleus WGS for a PGx Report
• 23andMe Pharmacogenetics: How to Get a Drug Response Report From Your Existing Data

That guide is the overview: why your Nebula WGS is enough, what Gene2Rx adds, how to get a report, and the price. This guide is the walkthrough: what your Gene2Rx report actually shows, what the phenotype calls mean in practice, and how WGS-specific advantages show up in the output. If you are new to pharmacogenetics, read the overview first. If you have Nebula data and want to know what a report looks like, this is the right page.

110 medications across every major drug class where CPIC or FDA has published pharmacogenetic guidance. That includes antidepressants (sertraline, escitalopram, citalopram, paroxetine, venlafaxine, amitriptyline, vortioxetine), antipsychotics (aripiprazole, brexpiprazole, clozapine), ADHD medications (atomoxetine, amphetamine), pain medications (codeine, tramadol), cardiovascular drugs (clopidogrel, warfarin, metoprolol, statins), PPIs (omeprazole, pantoprazole), chemotherapy agents (capecitabine, fluorouracil, mercaptopurine, azathioprine, tamoxifen), immunosuppressants (tacrolimus), and infectious-disease drugs (efavirenz, voriconazole).

Only in a limited way. Nebula provides optional interpretation tools, but it does not produce a dedicated CPIC- and FDA-anchored pharmacogenetic report covering 110 medications. Your Gene2Rx report gives a more complete drug-response picture from the same VCF.

A VCF file, which Nebula provides as part of your WGS data package. Look for the Data or raw data section of your member portal. If your Nebula data is available as both BAM and VCF, the VCF is what Gene2Rx needs.

Both reference genome builds are supported and auto-detected. Gene2Rx reads the build from the VCF header or infers it from variant positions, then maps pharmacogenetic loci correctly regardless. You do not need to lift over the file before uploading.

For life. Your genetics do not change. The clinical guidelines behind the report update occasionally as research emerges, so for high-stakes prescribing it is worth re-running the report from the same VCF every few years to catch material changes. For most uses, the report you generate today will still be accurate in 20 years.